Clinical trials
Colorectal cancer clinical trials
Cancer of the colon or rectum, often beginning as small growths called polyps. We’re tracking 1,068 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05093907RecruitingPhase 1/Phase 2
Testing a new cancer drug plus capecitabine for metastatic colon cancer
This trial studies whether BEY1107, a new treatment, is safe and works better when combined with capecitabine in people with metastatic colorectal (colon/rectum) cancer. It is aimed at cancers that have already progressed after standard chemotherapy.
Seoul, Jongro-goAges 19 years+ - NCT07309289RecruitingPhase 3
Comparing two drug combos for first-line metastatic colorectal cancer
This trial tests whether a combination of chemotherapy drugs (NALIRIFOX) plus targeted therapy works better than another standard combination (FOLFOX) plus targeted therapy for people with metastatic colorectal cancer who haven't had treatment yet. It aims to find a more effective first treatment option.
ShanghaiAges 18 years+ - NCT07284849RecruitingPhase 3
Testing a new drug combo for advanced colorectal cancer
This trial tests whether adding an experimental drug (INCA33890) to standard chemotherapy and bevacizumab helps people with a certain type of advanced colorectal cancer. It is for those whose cancer has spread and has not been treated yet with systemic therapy.
Mobile, AlabamaAges 18 years+ - NCT07263178Recruiting
Second-line chemo for advanced colorectal cancer
This study looks at different chemotherapy options for people with metastatic colorectal cancer that has stopped responding to first treatment. It aims to find which second-line approach works best.
SeoulAges 19 years+ - NCT05299840Recruiting
Test a device to choose the first chemo for metastatic colon cancer
This study tests whether using the Oncogramme® device to guide the first-line treatment improves care for people with metastatic colorectal (colon/rectum) cancer. If the device helps pick the most suitable standard chemotherapy plan, it could lead to better outcomes than choosing without it.
MarseilleAges 18 years+ - NCT07224815Recruiting
DNA markers to predict chemo response in advanced colon cancer
This study uses a blood test to look for specific DNA changes that may help predict how well chemotherapy works in people with metastatic colorectal cancer. The goal is to find markers that could guide future treatment decisions.
Duarte, CaliforniaAges 18 years+ - NCT07228832RecruitingPhase 3
Study of two drugs with chemo for advanced colorectal cancer
This clinical trial tests a new drug, ivonescimab, against an approved drug, bevacizumab. Both are given with standard chemotherapy (FOLFOX) for people with advanced colorectal cancer that has not been treated yet with chemo or other drugs.
Mobile, AlabamaAges 18 years+ - NCT05239338Recruiting
Preserving fertility after colorectal cancer
This study looks at how to help people protect their ability to have children after colorectal cancer. It mainly includes younger adults who were diagnosed for the first time and can complete study questionnaires.
Nashville, TennesseeAges 18–49 - NCT06783244Recruiting
Low vs standard belly pressure for robot colorectal cancer surgery
This trial is testing whether using lower air pressure inside the belly during robot-assisted colorectal cancer surgery helps patients recover better compared to the standard pressure. It aims to find a gentler approach that might reduce pain and improve recovery.
Copenhagen NVAges 18 years+ - NCT07171554Recruiting
A test to find the best drugs for advanced colorectal cancer
This trial uses a special test to help choose which drugs might work best for you if you have metastatic colorectal cancer that has stopped responding to first treatment. The goal is to match you with a more effective next therapy.
Lørenskog, AkershusAges 18 years+ - NCT06949982RecruitingPhase 2
Comparing two treatments for advanced colorectal cancer with RAS mutations
This trial tests if a combination of hydroxychloroquine, methotrexate, capecitabine, and bevacizumab works better than regorafenib for people with metastatic colorectal cancer that has a RAS gene mutation and has stopped responding to at least two prior treatments.
Saint Petersburg, Sankt-PeterburgAges 18 years+ - NCT07153458Recruiting
Finding new markers for colorectal cancer
This trial is looking for new, non-invasive markers to help detect and predict colorectal cancer. Researchers will study people with colorectal cancer, those with precancerous growths, and healthy people to find better ways to diagnose the disease.
Castellana GrotteAges 18 years+ - NCT06962670Recruiting
Cancer risk study using digital and molecular markers
This study uses a smartphone app and biological markers to predict cancer risk. It is testing whether digital and molecular data can help identify cancer earlier, especially in women with a history of certain cancers.
Please Refer to Project Homepage For Details (see Link Below), BavariaAges 18 years+ - NCT07133750RecruitingPhase 2
PM8002 plus chemo for untreated metastatic colorectal cancer
This trial tests a new combination therapy (PM8002 plus chemotherapy) for people with metastatic colorectal cancer who have not had prior treatment. It may be an option if your cancer is not MSI-H/dMMR and you are in good overall health.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03401294RecruitingPhase 2
Turn unresectable liver cancer into operable colorectal cancer
This Phase 2 study tests a treatment strategy to shrink or control colorectal cancer that has spread only to the liver, with the goal of making it removable by surgery. If you qualify, it may offer a chance to move from “not operable” to “operable,” but it’s still experimental.
Regina, SaskatchewanAges 18–70 - NCT07124858Recruiting
Fruquintinib for advanced colorectal cancer
This study tracks how well fruquintinib works for people with advanced colorectal cancer that has spread. It aims to find factors that predict better outcomes, using blood and tumor samples.
Poitiers, FranceAges 18 years+ - NCT07079631RecruitingPhase 1/Phase 2
Testing BNT314 with pumitamig and chemo for advanced colorectal cancer
This trial tests a new combination of drugs (BNT314 and pumitamig) plus chemotherapy for people with advanced colorectal cancer that has not responded to prior treatments. The goal is to see if this combination is safe and helps shrink or control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT06979908RecruitingPhase 2
A study of fruquintinib plus immunotherapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, a PD-1 inhibitor, and chidamide) for people with a specific type of advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
Changchun, JilinAges 18–75 - NCT06980532RecruitingPhase 1/Phase 2
Glumetinib and Fruquintinib for advanced colorectal cancer
This trial tests a combination of two targeted drugs (Glumetinib and Fruquintinib) for people with a specific type of advanced colorectal cancer that has a change in the MET gene (amplification) or too much MET protein. It is for those whose cancer has not responded to at least two prior treatments.
Wuhan, HubeiAges 18 years+ - NCT07042685RecruitingPhase 2
5-FU and Fruquintinib for advanced colorectal cancer
This trial tests a combination of two drugs (5-FU and fruquintinib) in people with advanced colorectal cancer that cannot be removed by surgery or has spread. It is for those who have not had chemotherapy before.
Houston, TexasAges 18 years+ - NCT07033156Recruiting
Colorectal cancer detection using gene methylation test
This study is testing a new way to detect colorectal cancer early by looking for specific changes (gene methylation) in stool and blood samples. If you are 40 or older and have a colonoscopy scheduled, this non-invasive approach might help find cancer sooner.
Hangzhou, ZhejiangAges 40 years+ - NCT05740956RecruitingPhase 1
Drug study for cancers with HRR gene or HRD changes
This Phase 1 study tests HS-10502 in people with advanced solid tumors that have certain DNA repair problems (HRR or HRD). It may help by finding a safe dose and seeing whether the drug can shrink tumors in cancers that have specific genetic features.
Beijing, Beijing MunicipalityAges 18–75 - NCT02328677Recruiting
Colorectal cancer study for newly diagnosed patients
This study enrolls people newly diagnosed with colon or rectal cancer to learn about their care and outcomes. You might be able to join if you meet the age, language, and consent requirements.
Los Angeles, CaliforniaAges 18–89 - NCT06885385RecruitingPhase 2
Study of JS207 with or without JS015 and chemo for colorectal cancer
This trial tests a new drug combination (JS207 with or without JS015) along with chemotherapy for people with advanced colorectal cancer that has not spread to other parts of the body. It aims to see if the treatment is safe and helps shrink tumors.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal cancer?
- Yes. Clin2 currently lists 1,068 recruiting colorectal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.